- In January 2021, IACTA Pharmaceuticals, Inc. and Pharmaleads (including Pharmaleads Greater China) entered into an exclusive global licensing agreement for Dual Enkephalinase Inhibitors (DENKI), targeting both acute (IC800) and chronic (IC805) ocular pain. The therapy aims to be the world’s first topical, epithelial‑protective drug that harnesses endogenous enkephalin‑mediated analgesia, offering a non‑opioid alternative for treating acute and chronic ocular pain. Under the agreement, Pharmaleads may receive up to USD 100 million through upfront, development, regulatory, and commercial milestones
